Interleukin 17 (IL-17)-producing helper T cells (T H 17 cells) require exposure to IL-23 to become encephalitogenic, but the mechanism by which IL-23 promotes their pathogenicity is not known. Here we found that IL-23 induced production of the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) in T H 17 cells and that GM-CSF had an essential role in their encephalitogenicity. Our findings identify a chief mechanism that underlies the important role of IL-23 in autoimmune diseases. IL-23 induced a positive feedback loop whereby GM-CSF secreted by T H 17 cells stimulated the production of IL-23 by antigen-presenting cells. Such cross-regulation of IL-23 and GM-CSF explains the similar pattern of resistance to autoimmunity when either of the two cytokines is absent and identifies T H 17 cells as a crucial source of GM-CSF in autoimmune inflammation.
A r t i c l e s T helper type 1 cells (T H 1 cells) and interleukin 17 (IL-17)-producing helper T cells (T H 17 cells) are mediators of central nervous system
(CNS) autoimmunity in both experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis 1 . The initial development of T H 17 cells from naive CD4 + T cells is directed by transforming growth factor-β (TGF-β) in combination with IL-6, IL-21 or IL-9 (refs. [2] [3] [4] [5] , and this process is enhanced by tumor necrosis factor (TNF) and IL-1β 6 , whereas IL-23 is required for the terminal differentiation of T H 17 cells into mature effector cells 7 . Two types of T H 17 cells, differing in their pathogenicity, have been described. T H 17 cells stimulated with TGF-β plus IL-6 have abundant production of IL-17A and IL-10 but are not pathogenic, which demonstrates that IL-17A production is not sufficient for the encephalitogenicity of T H 17 cells 8 . IL-10 has been shown to be not responsible for the nonpathogenic nature of these cells 8 . In contrast, stimulation with IL-23 results in highly encephalitogenic T H 17 cells, which demonstrates that IL-23 induces the expression of factors necessary for the effector functions of these cells. T H 17 cells secrete a range of inflammatory mediators, including IL-9, IL-17A, IL-17F, IL-21, IL-22, TNF and granulocyte-macrophage colony-stimulating factor (GM-CSF). The role of IL-17A in EAE is controversial, with findings ranging from its complete dispensability 9 to its being essential 10 . Similarly, the role of IL-9 is also controversial 3, 11 , whereas TNF, IL-21, IL-22 and IL-17F are not required for the development of EAE 9, [12] [13] [14] [15] . The failure to identify a soluble factor that mediates the encephalitogenicity of T H 17 cells has raised the question of whether the difference in pathogenicity of T H 17 cells stimulated with TGF-β plus IL-6 and those stimulated with IL-23 is caused by a secreted product or by a membrane-bound molecule(s).
Similar to mice deficient in IL-1, IL-6 or IL-23 (refs. [16] [17] [18] , mice deficient in GM-CSF do not develop EAE, nor do GM-CSFdeficient CD4 + T cells transfer EAE to naive recipients 19, 20 , which demonstrates an essential role for GM-CSF in the encephalitogenicity of T cells. GM-CSF secreted by CD4 + T cells, but not that secreted by dendritic cells, has been shown to be critical in the development of autoimmune myocarditis by promoting the production of IL-6 and IL-23 by dendritic cells, thereby enhancing T H 17 differentiation 21 . Moreover, a high frequency of CD4 + T cells isolated from the CNS of mice with EAE coexpress IL-17A and GM-CSF, which suggests that T H 17 cell-derived GM-CSF is involved in EAE development 21 .
GM-CSF is produced by T H 1, T H 2 and T H 17 cells 22, 23 and is the only known cytokine produced by T cells that is required for susceptibility to EAE. In this study, we identify GM-CSF as a critical factor in the pathogenicity of T H 1 and T H 17 cells. Nonpathogenic T H 17 cells treated with TGF-β plus IL-6 had lower expression of GM-CSF than did their pathogenic IL-23-driven counterparts, which provides a mechanistic basis for the action of IL-23 on T H 17 cells that renders them functionally mature. GM-CSF-deficient T H 17 cells were unable to induce EAE, which strengthens our hypothesis that T H 17 cells are a principal source of GM-CSF in this disease.
A r t i c l e s cells stimulated in various cytokine milieus. We first differentiated naive CD4 + T cells into T H 17 cells with TGF-β and IL-6 (first stimulation) and then reactivated the cells in the presence of various cytokines (second stimulation). During the first stimulation, a fraction of IL-17A + T cells expressed GM-CSF, and small amounts of GM-CSF were present in culture supernatants (Fig. 1a and data not shown). In the second stimulation, treatment with IL-23 resulted in a higher frequency of GM-CSF + T H 17 cells than that in cultures treated with TGF-β and IL-6 or without added cytokines (Fig. 1a,b) . The combination of IL-23, TGF-β and IL-6 did not result in a significantly higher frequency of GM-CSF + T H 17 cells above that obtained by stimulation with only TGF-β and IL-6 (Fig. 1a,b) . Consistent with that finding, IL-23 resulted in significant augmentation GM-CSF secretion, whereas TGF-β plus IL-6 or the combination of TGF-β, IL-6 and IL-23 resulted in modestly more GM-CSF production (Fig. 1c) . T H 17 cells restimulated either with TGF-β plus IL-6 or with TGF-β alone had less production of GM-CSF, whereas IL-6 did not have such a suppressive effect (Supplementary Figs. 1 and 2) . As described before 8 , T H 17 cells treated with TGF-β plus IL-6 had abundant secretion of IL-17A and IL-10 ( Fig. 1c) , and antibody blockade of IL-10 did not result in either a higher frequency of GM-CSF + T H 17 cells or more GM-CSF secretion (Fig. 1d,e) . Apoptosis and cell counts were similar in T H 17 cell cultures stimulated in the various conditions ( Supplementary Fig. 3 ), which indicated that differences in cell death or proliferation did not influence cytokine production. T H 17 cells differentiated by antigen-specific activation of splenocytes of 2D2 mice, which have transgenic expression of a T cell antigen receptor (TCR) specific for myelin oligodendrocyte glycoprotein amino acids ), also increased their production of GM-CSF during restimulation with IL-23 ( Supplementary Fig. 4a-c) . These results demonstrate that IL-23 induces GM-CSF expression by T H 17 cells, whereas TGF-β has a dominant suppressive effect.
To determine if helper T cells express the receptor for GM-CSF (GM-CSFR), which would render these cells susceptible to autocrine modulation by GM-CSF, we analyzed their expression of GM-CSFR. We did not detect the presence of GM-CSFRα mRNA in helper T cells, and flow cytometry confirmed the lack of surface expression of GM-CSFRα and GM-CSFRβ (Supplementary Fig. 5) . Furthermore, the differentiation of T H 17 cells was not affected by the addition of recombinant GM-CSF or blockade of endogenously produced GM-CSF (Supplementary Fig. 5c ). Our data are in agreement with published findings showing that CD4 + T cells do not express a receptor for GM-CSF 24, 25 and are thus not directly modulated by this cytokine.
To determine whether GM-CSF expression correlates with the pathogenicity of T H 17 cells, we transferred 2D2 T H 17 cells treated with TGF-β plus IL-6 or with IL-23 into sublethally irradiated recipient mice. Mice injected with IL-23-treated 2D2 T H 17 cells developed severe EAE, and all succumbed 7 d after disease onset, whereas among mice injected with 2D2 T H 17 cells treated with TGF-β and IL-6, only two of five mice developed mild disease ( Supplementary  Fig. 4d ). These results reproduce published findings demonstrating an essential role for IL-23 in the functional maturation of T H 17 cells and establishing a correlation between production of GM-CSF and encephalitogenicity of T H 17 cells 8 .
IL-1b upregulates GM-CSF production by T H 17 cells IL-1β and TNF promote the development of T H 17 cells 6 . To analyze the effect of these cytokines on GM-CSF production by committed T H 17 cells, we differentiated naive CD4 + T cells in the presence of TGF-β plus IL-6 and then restimulated them in the presence of either IL-23 or TGF-β plus IL-6, and IL-1β and/or TNF (Fig. 2) . The presence of IL-1β in addition to IL-23 resulted in a higher percentage of GM-CSF + cells, whereas TNF had minimal effects (Fig. 2a) . Consistent with those data, IL-1β resulted in greatly augmented secretion of GM-CSF and IL-17A, whereas TNF had a negligible effect (Fig. 2b) . The addition of TNF resulted in enhanced secretion of both IL-21 and IL-22, whereas the addition of IL-1β resulted in more secretion of only IL-22 (Fig. 2b) . IL-1β also stimulated the secretion of GM-CSF by T H 1 cells, whereas IL-12 and IL-23 had no effect (Supplementary Fig. 6 ). Notably, IL-1β in combination with IL-23 resulted in a greater proportion of GM-CSF + cells in the IL-17A − CD4 + population (Fig. 2a) . These IL-17A − GM-CSF + cells were not T H 1 cells because they did not produce interferon-γ (IFN-γ) and they expressed the transcription factor RORγt (data not shown).
We examined T H 17-specific markers in cells restimulated in the presence of IL-1β and/or TNF and found that expression of the aryl hydrocarbon receptor (AhR), the chemokine receptor CCR6 and the IL-23 receptor (IL-23R) was affected only modestly by the addition of IL-1β or TNF (Fig. 3) . Both IL-1β and TNF resulted in higher expression of RORα in all conditions tested. In contrast, IL-1β resulted in higher expression of the chemokine CCL20 in IL-23-restimulated T H 17 cells, whereas TNF did not have such an effect. A r t i c l e s Figs. 1 and 7) . Notably, IL-6 and, in particular, IL-23 counteracted the effect of TGF-β and resulted in a much lower proportion of CCR6 + T H 17 cells, whereas IL-1β had no effect. The ratio of CCR6 + GM-CSF + T H 17 cells to CCR6 + GM-CSF − T H 17 cells (approximately 1:1) was similar in all conditions tested, which demonstrated that expression of CCR6 and GM-CSF is regulated independently; this was also evident from the opposite effects of TGF-β and IL-23 on their expression. Among CNS-infiltrating CD4 + cells in EAE, 15-20% cells expressed CCR6 and approximately 30% expressed GM-CSF, but only a small fraction of cells (5%) coexpressed GM-CSF and CCR6 (Supplementary Fig. 8 ), which confirmed our in vitro finding that their expression was not correlated. We also found that lack of the transcription factor T-bet did not affect the expression of CCR6 on T H 17 cells (Supplementary Fig. 7) , which eliminated the possibility that the impaired encephalitogenicity of T-bet-deficient (Tbx21 −/− ) T H 17 cells was caused by a defect in CCR6 expression.
TGF-β strongly promoted CCR6 expression on committed T H 17 cells (Supplementary
IL-1β substantially up-modulated GM-CSF production by T H 1 and T H 17 cells, a finding that led us to examine expression of the IL-1 receptor (IL-1R) on these cells in EAE. IL-1R was expressed on 10-15% of CNS infiltrating CD4 + T cells. Only a minority (~15%) of GM-CSF + cells were also IL-1R + , whereas the highest percentage (20%) of IL-1R + cells was among IL-17A − IFN-γ − cells ( Supplementary  Fig. 9 and data not shown).
RORgt and T-bet are not required for GM-CSF production RORγt and T-bet are signature transcription factors of the T H 17 and T H 1 lineages, respectively, but T H 17 cells express T-bet as well 26 . In all conditions tested, the expression of RORγt and T-bet was higher in IL-17A + GM-CSF + cells than in IL-17A + GM-CSF − cells ( Supplementary Fig. 10a ), which suggested that RORγt and/or T-bet might regulate GM-CSF expression in T H 17 cells. Follow-up experiments showed that wild-type and Tbx21 −/− T H 17 cells produced similar quantities of GM-CSF in vitro and had similar responses to the cytokines that modify GM-CSF expression ( Supplementary  Figs. 2b,c and 7 ). In addition, splenocytes from immunized wildtype and Tbx21 −/− mice produced similar quantities of GM-CSF after stimulation with MOG(35-55) ex vivo (data not shown). Overall, these data demonstrate that T-bet is not necessary for normal GM-CSF expression in helper T cells.
We did similar experiments to assess the role of RORγt in GM-CSF production. 
activated in vitro produced quantities of GM-CSF similar to or larger than that of wild-type cells, depending on the cytokine milieu ( Fig. 2c  and Supplementary Fig. 10b) . Similarly, splenic cells of Rorc −/− mice also produced large quantities of GM-CSF, and Rorc −/− CD4 + cells included a percentage of GM-CSF + cells similar to that of wild-type CD4 + cells (data not shown). In contrast, splenocytes of Rorc −/− mice immunized with MOG(35-55) produced little GM-CSF after ex vivo restimulation with MOG(35-55) (Supplementary Fig. 10c,d ), which could have been due in part to the 50-70% lower abundance of CD4 + T cells among Rorc −/− splenocytes than among wild-type controls (data not shown). These data indicate that RORγt can have divergent roles in GM-CSF expression depending on the type and strength of signals that the cell receives from its environment.
T H 17 cells polarized without TGF-b produce GM-CSF
We also investigated GM-CSF production by T H 17 cells that developed in the presence of IL-1β, IL-6 and IL-23, an approach used for the differentiation of T H 17 cells without TGF-β 27 . The development of T H 17 cells in the absence of TGF-β was much less, as assessed by flow cytometry of IL-17A + cells and IL-17A secretion ( Supplementary  Fig. 11 ), whereas GM-CSF production was much greater, consistent with the inhibitory effect of TGF-β on GM-CSF production. This effect was even more pronounced in 2D2 splenic cultures than in those of purified CD4 + T cells (Supplementary Figs. 2d and 11) . Unexpectedly, after secondary stimulation these cells mostly ceased their IL-17A production while continuing to produce GM-CSF. Secretion of GM-CSF was not up-modulated by IL-23, whereas IL-1β resulted in considerably enhanced GM-CSF secretion. These findings indicate that T H 17 cells differentiated with IL-1β, IL-6 and IL-23 have a unique phenotype that requires further characterization.
GM-CSF contributes to the encephalitogenicity of T H 17 cells
To analyze GM-CSF expression in T H 17 cells that developed in vivo, we collected splenocytes from MOG(35-55)-immunized mice and stimulated the cells ex vivo. The frequency of IL-17A + GM-CSF + cells among CD4 + cells and GM-CSF production were similar in splenocytes stimulated in the presence of IL-23 or without added cytokines, but were less in cells treated with TGF-β and IL-6 (Fig. 4a-c) . Splenocytes treated with TGF-β plus IL-6 secreted more IL-17A and IL-10 ( Fig. 4c) , and the addition of neutralizing antibody to IL-10 (anti-IL-10) did not result in significantly more GM-CSF secretion but did result in augmented IL-17A production (Fig. 4d) . The results obtained with splenocytes from immunized mice did not fully reproduce the data obtained with isolated CD4 + T cells, as IL-23 did not upregulate GM-CSF expression. A potential explanation for this discrepancy is that sufficient quantities of endogenous IL-23 are secreted during culture to stimulate GM-CSF production similar to that in IL-23-treated samples. The addition of anti-IL-23p19 resulted in significantly less secretion of both GM-CSF and IL-17A (Fig. 4e) , which confirmed that endogenous IL-23 augments GM-CSF expression.
To investigate the role of GM-CSF in T H 17 cell pathogenicity, we obtained splenocytes from MOG(35-55)-immunized C57BL/6 mice, stimulated the cells in the presence of IL-23 and then injected them into sublethally irradiated recipient mice. Mice treated with anti-GM-CSF developed significantly milder disease, with delayed onset, relative to that of control mice injected with rat immunoglobulin G (IgG; Fig. 4f) . Three of five mice in the control group died, whereas all mice in the group treated with anti-GM-CSF survived. When treatment with anti-GM-CSF ended, mice began to develop more severe clinical signs of EAE (Fig. 4f) .
The data reported above suggested that GM-CSF produced by transferred helper T cells was not essential for EAE development. We addressed the possibility that irradiation abrogates the requirement for GM-CSF in the development of adoptive EAE and found that GM-CSF was indeed essential for EAE development in unirradiated recipients (Supplementary Fig. 12 ). That prompted us to continue our experiments without irradiation of recipient mice, an approach that we believe more faithfully reproduces natural processes. We also found that host cells had infiltrated the CNS and produced GM-CSF, which considerably modified disease course in irradiated recipients (Supplementary Fig. 12 ). Our data showing that highly polarized GM-CSF-deficient (Csf2 −/− ) T H 17 cells from mice with transgenic expression of a TCR specific for a peptide consisting of acetylated amino acids 1-11 of myelin basic 
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protein (MBP(Ac1-11)) induced EAE in irradiated recipients do not necessarily contradict a published report showing that nonpolarized cells from these mice are not encephalitogenic in irradiated recipients 20 . We used five times more highly polarized cells, which we believe explains discrepancies between our results and those published findings 20 .
GM-CSF-deficient T H 1 and T H 17 cells are non-encephalitogenic
Neutralization of GM-CSF during IL-23-driven adoptive EAE in irradiated recipients resulted in less-severe disease. Given that splenocytes of immunized mice included many helper T cell subsets (5.4% IL-17A + CD4 + T cells and 2.9% IFN-γ + CD4 + T cells), we could not draw a definitive conclusion about the relevant cellular source of GM-CSF. To circumvent this problem, we used splenocytes from GM-CSFsufficient and GM-CSF-deficient mice with transgenic expression of a TCR specific for MBP(Ac1-11) 20 to generate populations highly enriched for T H 1 and T H 17 cells and injected them into unirradiated recipients. In repeat experiments, the frequency of T H 1 and T H 17 cells and their cytokine production varied slightly in wild-type and Csf2 −/− cultures regardless of the presence or absence GM-CSF (Fig. 5a,b) , which confirmed a published report that GM-CSF has no effect on T H 17 development driven by exogenous cytokines 21 . Wild-type and Csf2 −/− cells had similar expression of AhR, CCL20, CCR6, IL-23R, RORα, RORγt and T-bet (Fig. 5c,d) .
Two of nine mice injected with Csf2 −/− T H 17 cells developed mild EAE, whereas all mice that received wild-type T H 17 cells developed severe disease. Similarly, all mice that received wild-type T H 1 cells developed EAE, whereas recipients of Csf2 −/− T H 1 cells did not ( Fig. 5e and Supplementary Fig. 13 ). The transgenic MBP(Ac1-11)-specific TCR contains the β-chain variable region 8. (Fig. 6) , which indicated that their failure to induce EAE did not result from their inability to migrate into the CNS. There were no consistent differences among the four experimental groups in the frequency of spinal cord-infiltrating CD4 + cells (data not shown), with CD4 + V β 8. (Fig. 6) . Together these data demonstrate that the encephalitogenicity of T H 1 cells and T H 17 cells depends on their GM-CSF production and that GM-CSF contributes to the maintenance of the T H 17 phenotype.
T H 17 cells induce IL-23 production from CD11c + cells
Published studies have demonstrated that GM-CSF can augment production of proinflammatory cytokines by antigen-presenting cells (APCs) 21, 28 . The production of IL-6 and IL-1β by purified splenic CD11c + cells was induced by deoxycytidylate phosphate deoxyguanylate-containing DNA (CpG) and by lipopolysaccharide (LPS) but not by anti-CD40 (data not shown). IL-23 production was induced by GM-CSF, CpG and, to a lesser extent, anti-CD40, whereas LPS had no effect (Fig. 7a) induced by anti-CD40, which suggested that GM-CSF produced by T cells enhanced IL-23 production by APCs. To test that hypothesis, we cultured CD11c + cells together with T H 17 cells that differed in their ability to produce GM-CSF. T H 17 cells treated with TGF-β plus IL-6 or with no added cytokines did not induce IL-23 production, whereas T H 17 cells treated with IL-23 triggered IL-23 secretion from CD11c + cells, which was blocked by neutralization of GM-CSF (Fig. 7b) .
The amount of IL-1β and IL-6 in T H 17 cell cocultures was similar in all conditions tested (Fig. 7c,d ). Together these data show that IL-23 can amplify its own production via the induction of GM-CSF secretion by T H 17 cells.
Given that GM-CSF affected IL-23 expression by APCs, we determined if it also modulated their IL-23R expression and therefore regulated the autocrine and/or paracrine effects of IL-23 on APCs. Bone marrow-derived dendritic cells had little or no expression of IL-23R, and various types of stimulation in combination with GM-CSF did not upregulate IL-23R expression (Supplementary Fig. 14) . CD11b + cells isolated from spleen did not express IL-23R, nor did they upregulate IL-23R expression in response to various stimuli and GM-CSF. In contrast, CD11c + cells from the spleen did express IL-23R, which was markedly upregulated by stimulation with LPS and CpG. However, GM-CSF had no effect on their IL-23R expression. Our findings are consistent with published work showing expression of IL-23R by only a small percentage of CD11b + and CD11c + cells from spleen 29 .
DISCUSSION
Here we assessed the regulation of GM-CSF production and found that IL-1β and IL-23 resulted in considerable upregulation of GM-CSF expression by T H 17 cells, which was required for EAE development. Our findings identify the IL-23-T H 17-GM-CSF axis as the main pathway in the pathogenesis of autoimmune CNS inflammation and probably other autoimmune diseases. T H 1 cells also produced GM-CSF and responded to IL-1β by increasing GM-CSF production, which means they are another possible source of GM-CSF in EAE. However, the finding that most CNS-infiltrating T H 1 cells originate from T H 17 cells 30 blurs the distinction between these two helper T cell lineages and makes unclear which is the principal source of GM-CSF in EAE. A plausible model can be proposed in which T H 17 cells and their T H 1 progeny ('ex-T H 17' cells) are essential in EAE, which includes the bulk of GM-CSF production, whereas classical T H 1 cells have a marginal role.
In a transfer model of colitis, RORγt-deficient T cells fail to induce disease and, when restimulated ex vivo, they produce much less IL-17A, GM-CSF and IFN-γ than do RORγt-sufficient T cells 31 . We found that IL-17A + GM-CSF + cells had higher expression of RORγt than did IL-17A + GM-CSF − cells, which indicates that RORγt may participate in GM-CSF expression in T H 17 cells. However, RORγt-deficient cells produced large quantities of GM-CSF in T H 17-polarizing conditions, which demonstrates that this transcription factor is not required for GM-CSF production by CD4 + T cells. This conclusion is consistent with the fact that highly polarized wild-type T H 1 cells, which do not express RORγt, also produce GM-CSF. In contrast to purified CD4 + T cells, splenocytes of Rorc −/− mice immunized with MOG(35-55) did not produce GM-CSF after ex vivo restimulation with MOG(35-55), whereas activation of the same splenocytes with anti-CD3 and anti-CD28 resulted in abundant GM-CSF secretion. Together our data have shown that RORγt is not absolutely needed for GM-CSF expression in CD4 + T cells, as strong mitogenic activation in vitro induced its production regardless of the presence or absence of RORγt, whereas CD4 + T cells that developed in vivo seem to require RORγt for optimal GM-CSF production. RORγt and RORα have synergistic and partially redundant functions during T H 17 polarization 32, 33 . Given that RORγt and RORα bind to highly homologous DNA motifs, it is possible that RORα can compensate for the absence of RORγt in GM-CSF expression as well.
T-bet expression in both T H 1 and T H 17 cells is necessary for their encephalitogenicity 26 . Given that T-bet has the role of master transcription factor in T H 1 lineage differentiation, the requirement for its expression in development of encephalitogenic T H 1 cells is apparent. However, its role in development and/or function of T H 17 cells is less clear. Given that the encephalitogenicity of T H 1 and T H 17 cells depends on both T-bet and GM-CSF, we hypothesized that T-bet has a role in GM-CSF production. However, wild-type and Tbx21 −/− T H 1 and T H 17 cells had similar production of GM-CSF and similar responses to the cytokines that modify GM-CSF expression. We also found that the lack of T-bet did not affect CCR6 expression on T H 17 cells, which eliminated the possibility that the impaired encephalitogenicity of Tbx21 −/− T H 17 cells was caused by a defect in expression of CCR6. It has been proposed that T-bet influences the function of T H 17 cells by directly regulating IL-23R expression 34 and/or by being required for IL-23 signaling 35 . However, in our experiments, the enhancement of IL-17A and GM-CSF production by IL-23 was even greater in Tbx21 −/− cells than in wild-type cells, which suggests that T-bet is not required for IL-23R expression or signaling.
The CCR6-CCL20 axis is essential for the entry of T H 17 cells into the CNS in the early phase of EAE 36 . The failure of Csf2 −/− T H 17 cells to induce EAE was not due to their inability to migrate to the CNS, given that wild-type and Csf2 −/− T H 17 cells had similar expression of CCR6 and CCL20 before transfer and infiltrated the CNS to a similar degree. We obtained similar results when we used wild-type and Csf2 −/− T H 1 cells to transfer EAE.
Our data and those of others have demonstrated that GM-CSF induces IL-23 in APCs, which in turn induce GM-CSF expression by T H 17 cells, resulting in amplification of the inflammatory response 21, 28, 37 . Given that a variety of lymphocyte subsets, such as cells of the T C 17 cytotoxic T cell subset, γδ T cells and natural killer T cells, express IL-23R [38] [39] [40] and can produce GM-CSF 37, 41, 42 , the IL-23-GM-CSF amplification loop probably involves those cell types in addition to T H 17 cells. In the effector phase of EAE, GM-CSF produced by encephalitogenic T cells is required for the development of disease by activation of CNS microglia 20 . Given that microglia are known producers of IL-23 (ref. 43) , the production of GM-CSF in the CNS by encephalitogenic T cells can in turn induce IL-23 production and promote local activation or population expansion-maturation of pathogenic T H 17 cells. Notably, IL-23-deficient mice develop EAE when exogenous IL-23 is delivered into the CNS, which indicates that IL-23 can act on already developed T H 17 cells 16 . It has been shown that GM-CSF produced by T cells indirectly promotes T H 17 differentiation and proliferation through stimulating the production of IL-6 and IL-23 by dendritic cells and macrophages 21 . Our data indicate that GM-CSF also has a role in maintenance of the T H 17 phenotype, as most Csf2 −/− T H 17 cells ceased IL-17A production and began to produce IFN-γ, whereas a much higher proportion of Csf2 +/+ cells retained the T H 17 phenotype. Given that helper T cells do not express GM-CSFR, the effect of GM-CSF in maintenance of T H 17 phenotype must be indirect, perhaps through the action of GM-CSF on APCs, which in turn secrete T H 17-promoting cytokines (such as IL-6 and IL-23).
It has been proposed that T H 17 and 'ex-T H 17' cells contribute mainly to CNS inflammation, as an unexpectedly small number of classical T H 1 cells is present in the CNS during EAE and they produce small amounts of cytokines, including GM-CSF 30 . Thus, even though classical T H 1 cells can produce GM-CSF, it seems that they are not an important source of this cytokine in EAE. It is not known if the T H 17-to-T H 1 phenotype switch is required for productive EAE pathogenesis or if T H 17 cells would establish productive CNS inflammation without the contribution of 'ex-T H 17' cells. T-bet is required for the encephalitogenicity of T H 17 cells 26 and for the switch from the T H 17 phenotype to the T H 1 phenotype, which raises the possibility that 'ex-T H 17' cells are crucial in EAE pathogenesis.
In conclusion, we have demonstrated that GM-CSF is required for the encephalitogenicity of both T H 1 and T H 17 cells. IL-23 induced GM-CSF production in T H 17 cells, whereas IL-1β potently enhanced GM-CSF production in both T H 1 and T H 17 cells. Our findings suggest that IL-23-induced GM-CSF production in T H 17 cells contributes to their phenotypic maturation into competent effector cells. However, in addition to inducing GM-CSF, IL-23 probably has other effects on T H 17 cells that promote their encephalitogenicity. We propose a positive feedback loop whereby IL-23 produced by APCs induces GM-CSF production by T H 17 cells, which in turn stimulates IL-23 production in APCs. Greater and/or prolonged production of IL-23 results in stronger and longer lasting T H 17 responses, causing more profound inflammation. The role of GM-CSF in the pathology of multiple sclerosis is unknown, but animal studies, including ours, suggest that blocking GM-CSF activity may be a successful therapeutic strategy for multiple sclerosis.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Note: Supplementary information is available on the Nature Immunology website.
